



Bubs Australia Limited 1H FY26 Results Presentation

27 February 2026



Disclaimer

This presentation is in summary form and is not necessarily complete. It should be read together with the Company's other announcements lodged with the Australian Securities Exchange.

This presentation contains information that is based on projected and/or estimated expectations, assumptions or outcomes. Forward looking statements are subject to a range of risk factors. The Company cautions against reliance on any forward-looking statements, particularly in light of the current economic climate, the need for approvals from relevant regulators, changes in consumer shopping behavior and demand in international markets, as well as the costs and implications of any potential litigation.

While the Company has prepared this information based on its current knowledge and understanding and in good faith, there are risks, uncertainties and factors beyond the Company's control which could cause results to differ from projections. The Company will not be liable for the correctness and/or accuracy of the information, nor any differences between the information provided and actual outcomes and reserves the right to change its projections from time to time. The Company undertakes no obligation to update any forward-looking statement to reflect events or circumstances after the date of this presentation, subject to disclosure obligations under applicable law and ASX listing rules.

This presentation is for information purposes only and is not a product disclosure statement or prospectus, financial product or investment advice or a recommendation to acquire securities.

The Company's results are reported under International Financial Reporting Standards (IFRS). However, this presentation contains non-IFRS financial measures to provide a more comprehensive understanding of the Company's performance. Non-IFRS measures are not subject to audit or review.

All currency referred to in this document is in Australian dollars, unless otherwise stated.

Acknowledgement of Country

Bubs acknowledges the Traditional Custodians of the Lands on which we operate.

We pay our respects to Elders past and present.



Image: Bunurong Marine National Park of Victoria


Presenters



Joe Coote
Chief Executive Officer



Naomi Verloop
Chief Financial Officer




Contents

Result Highlights **6**

Update by Market **7**

Financial Results **13**

Strategy Update **21**



On track to exceed FY26 commitments

Results achieved through strategic clarity, focused growth and disciplined execution

**1H Revenue
growth**

\$55.5M

**Gross
profit >than
40%**

48%

**Positive
Underlying
EBITDA¹**

\$4.4M

**Upgraded FY26
outlook driven
by performance
in strategic
markets**

Highlights

- Deployment of initiatives aligned with 2030 Strategy pillars
- Acceleration of high performance culture
- Progression on USA permanent access

¹ Underlying Earnings before Interest, Tax, Depreciation and Amortisation (Underlying EBITDA) is a non-IFRS measure. Non-IFRS measures have not been subject to audit or review.



**Update by
Market**

We operate in a dynamic global environment



Macro demographic forces

- Mass market impacted by declining birth rates¹
- Growing demand for premium, natural formula



Regulatory and geopolitical landscape

- Volatility in currency and interest rates
- Shifting tariff policies altering global trade dynamics




Consumer and competitive dynamics

- Cost of living pressures
- Evolving product quality expectations

We are well-positioned...

- ✓ Strong brand equity
- ✓ Diversified markets
- ✓ Attractive margin structure



- Strategic markets
- Growth markets
- Partner markets
- Distribution
- ▲ Manufacturing

¹ National Bureau of Statistics of China, via CNBC: China's birth rate fell to 5.6 per 1,000 people, the lowest on record 19/01/2026

Strong volume and value growth in the US

Strong retail performance, which has been rewarded by significant ranging increases by retailers

Strong category growth

- Total market growth +3% vs premium natural +44%
- Bubs 1% of total market and 8% of premium natural

Increased ranging with key retailers and service level maintained

- Enhanced retailer relationships as a result of responsiveness to market changes
- Air freight program well executed with service level maintained

Marketing


- Re-weighting and increasing spend to TikTok and Reddit
- Hyper geographical focus on target consumer segments via Digital + Traditional + Health Care Professional (HCP) + Retail trade

Retail ranging extensions and launches



USA
\$34.2M
+48% on pcp

59% projected increase in US Store Count



Encouraging China performance

Growth increasingly concentrated in lower tier cities, with parents shifting to premium products

O2O distribution continues to scale

- O2O Mother & Baby store expansion, store count +77% pcp (1783 stores)
- Sell-through +50% pcp

CBEC volume growth

- CBEC IMF sales +30% pcp vs category average 13%
- Tmall Global Flagship Store ranked #1 in the CBEC Goat IMF category¹
- Launched Douyin (TikTok) Flagship Store

Marketing and Portfolio enhancements

- New product extension in growing-up kids and China-label CapriLac for adults
- Stock rationing complete and sell-in / sell-out inventory re-balanced
- Increased investment in TikTok to drive brand equity and customer acquisition.



China
\$7.5M
-27% on pcp



Strong channel growth
O2O +50% pcp; CBEC +30% pcp



¹ Source: MetriCo.com, Tmall & JD.com Goat IMF GMV (CBEC) as at 31/12/2026
All figures on this slide are in AUD

Investing to re-establish growth in Australia

Maintained #1 goat infant formula position in Australia¹

Actions taken to reinvigorate growth

- Increased marketing investment from 8% of net sales in Q1 to 12%
- Focused activations aligned with brand DNA of clean label, gentle tummies and Proudly Australian
 - Invested in price with positive consumer and retailer response
 - Commenced Health Care professional engagement
- Investment in commercial and marketing leadership
- Improved on-shelf availability through stock prioritisation

Sharpening portfolio execution

- Food portfolio discontinued to streamline operations



Australia
\$9.5M
-9% on pcp



Resilient ROW performance

Strong distributor partnerships across key markets, driving stability and sell-through growth

Japan

- Optimising route-to-market across all three available sale channels
- Introducing first-purchase incentive


Vietnam

- Signed sole distributor with extensive experience including Health Care Professional network
- Maintained supply during regulatory challenges and stock rationing

Malaysia

- Increased brand awareness amongst HCP
- Doubled distribution points in the past 12 months

ROW
\$4.2M
-8% on pcp



Financial Results



Strong momentum driving double-digit revenue growth

Uplift in revenue with positive underlying EBITDA

Revenue

Up 14% overall \$55.5 million, driven by a 48% increase in USA revenue versus prior corresponding period (pcp).

Gross Profit

Increased 9% to \$26.6 million, reflecting stronger product mix from higher margin US revenues, despite additional airfreight and tariffs incurred on non-AU sourced goat milk solids.

Operating Expenses

Down 3%, primarily due to the completion of FDA growth studies

Underlying EBITDA

Increased to \$4.4 million, representing a significant uplift to underlying earnings as revenue growth outpaces operating costs.

Income statement		
\$'M	1HY26	1HY25
Revenue	55.5	48.5
Gross Profit	26.6	24.4
<i>Gross profit (%)</i>	<i>48%</i>	<i>50%</i>
Other income / (expense)	0.8	1.3
Operating expenses		
Distribution	(3.7)	(3.8)
Marketing	(7.7)	(7.6)
Administrative and other costs ²	(13.1)	(13.8)
Total Operating expenses	(24.5)	(25.2)
EBITDA² (loss) / profit	3.0	0.6
Depreciation & amortisation	(0.6)	(0.4)
Net finance income/expense	(0.6)	3.4
Net profit / (loss) after tax	1.8	3.6
Underlying EBITDA³ profit / (loss)	4.4	(0.7)

¹ Administration and other costs do not include depreciation & amortisation costs.

² EBITDA is a non-IFRS term and refers to Earnings before Interest, Tax, Depreciation and Amortisation. Non-IFRS measures have not been subject to audit or review.

³ Underlying Earnings before Interest, Tax, Depreciation and Amortisation (Underlying EBITDA) is a non-IFRS measure. Non-IFRS measures have not been subject to audit or review. Excludes proceeds from insurance claims \$1.3m (1H FY25), proceeds from Alice & Willis settlement \$0.8m (1H FY26), Air freight costs & Non-AU tariff \$2.2m (1H FY26)

Figures in above table may differ to financial statements due to rounding

Strong operating result and working capital management foundations

Inventory rebuild drove increase in Net Assets to \$45.5M

Cash and cash equivalents of \$9.9M at Dec-25 reflecting inventory investment in 1H to support sales growth.

Trade and other receivables increased by \$3.7M due to strong revenue growth.

Inventories increased by \$8.0M due to inventory build required to meet growing sales in the USA and ensure supply continuity across all markets.

Right of use assets increased by \$5.3M reflecting the accounting treatment for the new leasing contracts of the Dandenong South manufacturing, warehousing and office facilities.

Trade and other payables increased by \$5.4M, largely due to increased purchases of raw materials to support the inventory rebuild

Balance Sheet		
\$'M	Dec-25	Jun-25
Cash and cash equivalents	9.9	17.4
Trade and other receivables	14.3	10.6
Inventories	28.1	20.1
Other current assets	4.5	2.8
Current assets	56.8	50.9
Plant and equipment	3.9	3.7
Right of use assets	6.1	0.8
Intangible assets	1.9	1.2
Other non-current assets	0.6	0.6
Non-current assets	12.4	6.3
Trade and other payables	15.7	10.3
Other current liabilities	2.2	3.0
Lease liabilities	0.9	0.7
Current liabilities	18.8	13.9
Lease liabilities	5.4	0.3
Other non-current liabilities	0.5	0.5
Non-current liabilities	6.0	0.8
Net assets	44.5	42.5

Increased payments to suppliers to build inventory position

Reinvesting operating cash to secure inventory for growth markets

Net cash used in operating activities decreased by \$5.2M, a reflection of the working capital investment required to support higher inventory levels to fund growth


Overall cash position has decreased by \$7.5m since June 2025 due to inventory rebuild and investments in ensuring continued supply.

Cash Flow		
\$'M	Dec-25	Dec-24
Cash flows from operating activities		
Receipts from customers	55.3	46.7
Payments to suppliers ,employees and government	(60.8)	(47.1)
Interest received	0.1	0.2
Interest paid	(0.2)	(0.3)
Net cash from/(used in) operating activities	(5.7)	(0.5)
Cash flows from investing Activities		
Purchases of property, plant and equipment	(0.3)	-
Purchases of intangible assets	(0.7)	-
Net cash from/(used in) investing activities	(1.0)	-
Cash flows from financing activities		
Repayment of lease liabilities	(0.8)	(0.4)
Net cash from/(used in) financing activities	(0.8)	(0.4)
Net increase/(decrease) in cash and cash equivalents	(7.5)	(0.8)
Cash and cash equivalents at beginning of financial year	17.4	17.5
Effects of exchange rates on cash held	0.0	0.6
Total cash and cash equivalents at the end of the period	9.9	17.2

Strategic margin and inventory management

High margin growth in core markets

Total Group Gross Profit



Margin Resilience

High-margin US sales as well as a lower level of non-AU milk solids defended Gross Profit % against impacts of tariffs and airfreight

Resource Allocation



Prioritised high-margin US growth by rationing raw materials from secondary regions; recovery in these markets is forecasted for 2H as supply normalises.

Demand Fulfillment & Market Capture

Expedited air freight in 1H to manage goat solid constraints and meet unprecedented demand without losing shelf continuity.

Disciplined approach to working capital

Working capital positioned for inventory expansion for sustainable growth




- Disciplined approach to working capital to ensure sufficient funds available to meet short term business obligations
- Average net working capital increasing to \$33.4m to fund inventory re-build, however strong revenue growth leading to improved efficiency on ANWC as % of sales
- Inventory balances increasing to fund growing demand across key markets, whilst maintaining healthy levels as a proportion of revenue

¹ Net Working Capital = Current Assets (excluding cash and cash equivalents), less Trade and other payables. This is a Non-IFRS measure. Non-IFRS measures have not been subject to audit or review.

FY26 EBITDA guidance

Strong underlying EBITDA result despite supply constraints impacting FY26 performance

FY25 Underlying EBITDA to FY26 EBITDA guidance¹ (\$AUD Millions)



¹ Subject to tariff review

FY26 outlook upgraded

1H FY26 performance

Full Year FY26 guidance

Revenue¹

\$55.5M

\$120.0M – \$125.0M, reflecting 22-27% growth on prior year

Gross profit %

48%

40 – 45%

EBITDA²

\$3.0M

\$4.0M – 6.0M

Underlying EBITDA³

\$4.4M

\$9.0M – 11.0M

¹ Revenue represents the revenue recognised after trading terms, trade spend and promotional support.


² Earnings before interest, tax, depreciation and amortisation.

³ Underlying Earnings before Interest, Tax, Depreciation and Amortisation (Underlying EBITDA) is a non-IFRS measure. Non-IFRS measures have not been subject to audit or review.


Strategy Update



Deploying our 2030 strategy



Increasing pace and progress of our strategy deployment



✓ Delivered ▲ In progress

Questions & Answers

